CND Life Sciences supports the care of patients facing the potential diagnosis of neurodegenerative disease and other neurological conditions. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, CND developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure and REM sleep behavior disorder. Syn-One uses proprietary immunofluorescence techniques to detect, visualize and quantify phosphorylated alpha-synuclein in cutaneous nerves. Results of a prospective, multicenter NIH-sponsored study of the Syn-One Test were published in the Journal of the American Medical Association (JAMA) in 2024 demonstrating >95% sensitivity overall in patients with a clinically determined synucleinopathy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/01/25 | $13,500,000 | Series A |
BlueStone Ventures Cambrian Capital Partners Gold Bench Capital HonorHealth LabCorp Lupo Labs MBX Capital Tanis Ventures Top Corner Capital Triana Vilas Ventures | undisclosed |
